15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 学术讨论& HBV English 先进医学实验室在2019年肝脏会议上展示新的肝癌测试数据 ...
查看: 547|回复: 1
go

先进医学实验室在2019年肝脏会议上展示新的肝癌测试数据 [复制链接]

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

1
发表于 2019-11-13 12:22 |只看该作者 |倒序浏览 |打印

Laboratory for Advanced Medicine Presents New Liver Cancer Test Data at The Liver Meeting 2019

- Test's liver cancer detection is superior to current standard of care, new data supports -
Laboratory for Advanced Medicine (LAM) Logo (PRNewsfoto/Laboratory for Advanced Medicin)

News provided by
Laboratory for Advanced Medicine (LAM)

Nov 12, 2019, 18:04 ET

IRVINE, Calif., Nov. 12, 2019 /PRNewswire/ -- Laboratory for Advanced Medicine, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced that it will be presenting new data supporting its methylation-based liver cancer diagnostic test at The Liver Meeting® 2019 hosted by the American Association for the Study of Liver Diseases (AASLD), taking place in Boston from Nov. 8-12.  AASLD selected Laboratory for Advanced Medicine's data for poster presentation as a "Poster of Distinction."  Posters of Distinction are classified as being in the top 10% of scored poster abstracts.

Data from the presentation, titled "A DNA Methylation-Based Diagnostic Platform: Towards Early Detection of Hepatocellular Carcinoma," suggests that using the DNA methylation panel for hepatocellular carcinoma (HCC) provides superior performance than the current standard of care screening methods such as ultrasound and alpha-fetoprotein. This analysis evaluated blood samples from 450 subjects by using DNA methylation technology which correctly detected HCC in patients for an overall sensitivity of 88% (n= 218/249) and correctly identified 96% of healthy donors (n= 80/83) and 98% of patients with benign disease (n=116/118) with a combined specificity of 97%.

"These results highlight the importance of continued development and validation of blood-based DNA methylation biomarkers for detecting liver cancer early," said Dhruvajyoti Roy, PhD, Director of Technology at LAM. "The new results and continued validations strongly support Laboratory for Advanced Medicine's ongoing clinical trial to evaluate the performance of the liver cancer test for the detection of HCC within a high risk population."

AASLD Poster Presentation Details:

Abstract Number: 0843

Abstract Title: "A DNA METHYLATION-BASED DIAGNOSTIC PLATFORM: TOWARDS EARLY DETECTION OF HEPATOCELLULAR CARCINOMA"

Location: Hynes Convention Center, Hall B

Poster Session Date: Saturday, November 9, 2019

Poster Session Time: 2:00 PM – 7:00 PM

About Laboratory for Advanced Medicine

Laboratory for Advanced Medicine is an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw. For over 10 years, Laboratory for Advanced Medicine has used AI on over 100,000 samples to identify cfDNA methylation patterns that detect cancer early.   The company is currently in clinical trials in the US and China with its leading product to detect liver cancer.  Its pipeline includes colon and breast cancer, as well as 20 other cancers.

Laboratory for Advanced Medicine is headquartered in Irvine, CA, with R&D, GMP and CLIA facilities in Irvine, CA and West Lafayette, IN, Guangzhou and Beijing.

SOURCE Laboratory for Advanced Medicine (LAM)

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

2
发表于 2019-11-13 12:22 |只看该作者
先进医学实验室在2019年肝脏会议上展示新的肝癌测试数据

-测试的肝癌检测优于目前的医疗标准,新数据支持-
先进医学实验室(LAM)徽标(PRNewsfoto /先进医学实验室)

新闻提供者
先进医学实验室(LAM)

美国东部时间2019年11月12日18:04

加利福尼亚州IRVINE,2019年11月12日/美通社/-先进医学实验室是一家由AI驱动的医疗保健公司,致力于通过简单的抽血将早期癌症检测测试商业化,今天宣布它将提供支持其早期研究的新数据。由美国肝病研究协会(AASLD)主办的The LiverMeeting®2019的基于甲基化的肝癌诊断测试将于11月8日至12日在波士顿举行。 AASLD选择了高级医学实验室的数据进行海报展示,以作为“杰出海报”。杰出的海报被列为得分最高的摘要中前10%。

演讲中的数据名为“基于DNA甲基化的诊断平台:早期发现肝细胞癌”,这表明使用DNA甲基化面板治疗肝细胞癌(HCC)的性能要优于当前的标准护理筛查方法,例如超声和甲胎蛋白。该分析通过使用DNA甲基化技术评估了450位受试者的血液样本,该技术可正确检测患者的HCC,总敏感性为88%(n = 218/249),并正确识别出96%的健康捐献者(n = 80/83)和98 %的良性疾病患者(n = 116/118),特异性为97%。

LAM技术总监Dhruvajyoti Roy博士说:“这些结果突显了继续开发和验证基于血液的DNA甲基化生物标记物对早期检测肝癌的重要性。 “新的结果和持续的验证有力地支持了高级医学实验室正在进行的临床试验,以评估在高风险人群中检测肝癌以检测HCC的性能。”

AASLD海报介绍细节:

摘要编号:0843

摘要标题:“基于DNA甲基化的诊断平台:有助于早期检测肝细胞癌”

地点:海因斯会议中心B厅

海报发布日期:2019年11月9日,星期六

海报发布时间:2:00 PM – 7:00 PM

关于高级医学实验室

Advanced Medicine实验室是一家由AI驱动的医疗保健公司,致力于通过简单的抽血使早期癌症检测测试商业化。十多年来,高级医学实验室已使用AI对100,000多个样本进行识别,以识别可早期检测癌症的cfDNA甲基化模式。该公司目前正在美国和中国进行临床试验,其主要产品可检测肝癌。它的产品线包括结肠癌和乳腺癌,以及其他20种癌症。

先进医学实验室的总部位于加利福尼亚州欧文,在加利福尼亚州欧文以及印第安那州西拉斐特,广州和北京设有研发,GMP和CLIA设施。

消息来源高级医学实验室(LAM)
‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册

肝胆相照论坛

GMT+8, 2024-11-20 17:52 , Processed in 0.013567 second(s), 11 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.